Current status of intra-arterial chemotherapy for retinoblastoma
Retinoblastoma(RB),a common malignant tumor of the eye in children,has been con-tinuously evolving in its treatment methods as medical technology advances and greater attention is paid to patients'quality of life.In recent years,intra-arterial chemotherapy(IAC)has become an important treat-ment modality for RB,achieving targeted local chemotherapy of the tumor through ophthalmic artery drug de-livery,significantly improving treatment outcomes and reducing systemic adverse reactions.This article pro-vides a comprehensive review of the technical operation,chemotherapeutic drugs(melphalan,carboplatin,topotecan),eye and systemic adverse reactions,prognosis,and limitations of IAC in the treatment of RB,aiming to provide reference value for the improvement and development of IAC in clinical practice.(Int Rev Ophthalmol,2024,48:476-480)
万方数据
